Keyword: House Committee on Oversight and Government Reform
Congress may be busy investigating Mylan and its EpiPen pricing, but that doesn’t mean its watchdog committees can’t turn a spotlight on pharmacy benefits managers, too. And a group of pharmacists is demanding that they do just that.
The EpiPen drama is moving into a congressional hearing room. Mylan CEO Heather Bresch is on the docket to testify next Wednesday for the House Committee on Oversight and Government Reform, where she’ll face questions about her company’s price hikes on the lifesaving epinephrine injector.